

WOAH Reference Laboratory Reports Activities 2022

Activities in 2022

This report has been submitted : 9 mars 2023 17:56

Laboratory Information

Name of disease (or topic) for which you are a designated WOA Reference Laboratory:	Contagious Caprine Pleuropneumonia
Address of laboratory:	CIRAD, Département BIOS TA A-117/E Campus International de Baillarguet 34398 Montpellier Cedex 5 France
Tel.:	0033467593723
E-mail address:	lucia.manso-silvan@cirad.fr
Website:	
Name (including Title) of Head of Laboratory (Responsible Official):	Dr Nathalie Vachier
Name (including Title and Position) of WOA Reference Expert:	Dr Lucia Manso-Silvan
Which of the following defines your laboratory? Check all that apply:	

TOR1: DIAGNOSTIC METHODS

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in WOA Manual (Yes/No)	Total number of test performed last year	
Indirect diagnostic tests		Nationally	Internationally
CCPP cELISA (IDEXX)	Yes		225
Direct diagnostic tests		Nationally	Internationally

TOR2: REFERENCE MATERIAL

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by WOA?

No

3. Did your laboratory supply standard reference reagents (nonWOAH-approved) and/or other diagnostic reagents to WOAH Members?

Yes

TYPE OF REAGENT AVAILABLE	RELATED DIAGNOSTIC TEST	PRODUCED/ PROVIDE	AMOUNT SUPPLIED NATIONALLY (ML, MG)	AMOUNT SUPPLIED INTERNATIONALLY (ML, MG)	NO. OF RECIPIENT WOAH MEMBER COUNTRIES	COUNTRY OF RECIPIENTS
CCPP cELISA	CCPP cELISA kit (IDEXX)	provided		1 kit (400 reactions)	1	Europe
Internal reference sera	cELISA	produced/provided		1	1	Europe
CCPP PCR kit	PCR	provided		1 kit (100 reactions)	1	Europe
CCPP PCR control DNAs	PCR	produced/provided		4	1	Europe
CCPP PCR primers	PCR	provided		2	1	Africa

4. Did your laboratory produce vaccines?

Yes

5. Did your laboratory supply vaccines to WOAH Members?

Yes

VACCINE NAME	AMOUNT SUPPLIED NATIONALLY	AMOUNT SUPPLIED NATIONALLY (ML, MG)	NAME OF RECIPIENT WOAH MEMBERS
CCPP inactivated vaccine: Mccp strain Abomsa antigens quality-controlled by bacteriology and mass spectrometry analyses, in Montanide ISA61VG adjuvant (SEPPIC)		400 doses	CHAD

TOR3: NEW PROCEDURES

6. Did your laboratory develop new diagnostic methods for the designated pathogen or disease?

Yes

7. Did your laboratory validate diagnostic methods according to WOAH Standards for the designated pathogen or disease?

Yes

NAME OF THE NEW TEST OR DIAGNOSTIC METHOD DEVELOPED	DESCRIPTION AND REFERENCES (PUBLICATION, WEBSITE, ETC.)
CCPP qPCR	Ongoing validation for direct detection from lung tissues, pleural fluid and lymph-nodes and for identification of isolates

8. Did your laboratory develop new vaccines for the designated pathogen or disease?

No

9. Did your laboratory validate vaccines according to WOAH Standards for the designated pathogen or disease?

No

TOR4: DIAGNOSTIC TESTING FACILITIES

10. Did your laboratory carry out diagnostic testing for other WOA Member?

Yes

NAME OF WOA MEMBER COUNTRY SEEKING ASSISTANCE	DATE	WHICH DIAGNOSTIC TEST USED	NO. SAMPLES RECEIVED FOR PROVISION OF DIAGNOSTIC SUPPORT	NO. SAMPLES RECEIVED FOR PROVISION OF CONFIRMATORY DIAGNOSES
PAKISTAN	2022-01-03	Multi-locus sequence typing	1	
CHINA (PEOPLE'S REP. OF)	2022-01-03	Multi-locus sequence typing	6	
CHAD UNITED ARAB EMIRATES	2022-11-14	CCPP vaccine quality control by Mass spectrometry	1	

11. Did your laboratory provide expert advice in technical consultancies on the request of an WOA Member?

Yes

NAME OF THE WOA MEMBER COUNTRY RECEIVING A TECHNICAL CONSULTANCY	PURPOSE	HOW THE ADVICE WAS PROVIDED
CHAD	Possibility of collaboration with IRED for capacity building in animal disease diagnostics	Visit to CIRAD of IRED Director

TOR5: COLLABORATIVE SCIENTIFIC AND TECHNICAL STUDIES

12. Did your laboratory participate in international scientific studies in collaboration with WOA Members other than the own?

Yes

Title of the study	Duration	PURPOSE OF THE STUDY	PARTNERS (INSTITUTIONS)	WOAH MEMBER COUNTRIES INVOLVED OTHER THAN YOUR COUNTRY
Multivalent approach for the improvement of inactivated vaccines against small ruminant diseases in Africa (MultiVacc)	4 years	Improved inactivated vaccines against CCPP and heartwater	CIRAD, France (coordinator); KALRO, Kenya; CIRDES Burkina Faso; ILRI, Kenya	BURKINA FASO KENYA
Mccp MLSA	1 year	Update MLSA data, particularly by including Asian strains	CIRAD, France (coordinator), Lanzhou Veterinary Research Institute, China; University of Agriculture, Peshawar, Pakistan	CHINA (PEOPLE'S REP. OF) FRANCE PAKISTAN
DISCONTTOOLS CCPP gap analysis	6 months	CCPP disease and products gap analysis	CIRAD (coordinator), international consortium	CHINA (PEOPLE'S REP. OF) GERMANY ITALY KENYA MOROCCO UNITED STATES OF AMERICA
		Standardisation of		

JPI AMR MyMIC	2 years	diagnostic and AMR determination tests and clinical interpretation in mycoplasmas pathogenic for animals	ANSES (coordinator) ; large international consortium	FRANCE
RFOROA One health	1 year	Diagnostic support	IRED, Smithsonian Institute	CHAD UNITED STATES OF AMERICA

TOR6: EPIZOOLOGICAL DATA

14. Did your Laboratory collect epidemiological data relevant to international disease control?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Multi-locus sequence data and metadata from whole genome sequences of Mccp strains available in public databases, as well as new data obtained from China and Pakistan (cf. Akhtar et al, 2022)

15. Did your laboratory disseminate epidemiological data that had been processed and analysed?

Yes

IF THE ANSWER IS YES, PLEASE PROVIDE DETAILS OF THE DATA COLLECTED:

Akhtar, Arooba; Anne Boissière; Huafang Hao; Muhammad Saeed; Virginie Dupuy; Antoni Exbrayat; Farhan Anwar Khan; Yuefeng Chu; Lucía Manso-Silván (2022). Multi-locus sequence analysis reveals great genetic diversity among *Mycoplasma capricolum* subsp. *capripneumoniae* strains in Asia. *Vet Res* (2022) 53:92 <https://doi.org/10.1186/s13567-022-01107-z>

16. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category and list the details in the box)

a) Articles published in peer-reviewed journals:

1

Akhtar, Arooba; Anne Boissière; Huafang Hao; Muhammad Saeed; Virginie Dupuy; Antoni Exbrayat; Farhan Anwar Khan; Yuefeng Chu; Lucía Manso-Silván (2022). Multi-locus sequence analysis reveals great genetic diversity among *Mycoplasma capricolum* subsp. *capripneumoniae* strains in Asia. *Vet Res* (2022) 53:92 <https://doi.org/10.1186/s13567-022-01107-z>

b) International conferences:

c) National conferences:

d) Other (Provide website address or link to appropriate information):

TOR7: SCIENTIFIC AND TECHNICAL TRAINING

17. Did your laboratory provide scientific and technical training to laboratory personnel from other WOAHA Members?

Yes

a) Technical visit :

b) Seminars : 30

c) Hands-on training courses: 30

d) Internships (> 1 month)

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
b	30 different countries of Africa and Asia	
c	30 different countries of Africa and Asia	

TOR8: QUALITY ASSURANCE

18. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)	
ISO 17025	« Accréditation COFRAC Essais, CIRAD n° 1-2207, portée disponible sous www.cofrac.fr . »	Attestation Accréditation COFRAC Essais, CIRAD n° 1-2207_Jan2023.pdf

19. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
Semi-quantitative ELISA	COFRAC

20. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

TOR9: SCIENTIFIC MEETINGS

21. Did your laboratory organise scientific meetings related to the pathogen in question on behalf of WOAHA?

No

22. Did your laboratory participate in scientific meetings related to the pathogen in question on behalf of WOAHA?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short)	Title of the work presented
----------------	--------------	----------	--	-----------------------------

			communications)	
Discontools gap analysis group meeting	2022-12-13	Videoconference	Project coordinator	CCPP gap analysis

TOR10: NETWORK WITH WOAHP REFERENCE LABORATORIES

23. Did your laboratory exchange information with other WOAHP Reference Laboratories designated for the same pathogen or disease?

No

24. Are you a member of a network of WOAHP Reference Laboratories designated for the same pathogen?

No

25. Did you organise or participate in inter-laboratory proficiency tests with WOAHP Reference Laboratories designated for the same pathogen?

No

26. Did your laboratory collaborate with other WOAHP Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

TOR11: OTHER INTERLABORATORY PROFICIENCY TESTING

27. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than WOAHP Reference Laboratories for the same pathogen?

Yes

Purpose for inter-laboratory test comparisons ¹	Role of your reference laboratory (organizer/participant)	No. participating laboratories	Region(s) of participating WOAHP Member Countries
CCPP cELISA PT	Organiser	3	Africa Europe

TOR12: EXPERT CONSULTANTS

28. Did your laboratory place expert consultants at the disposal of WOAHP?

No

29. Additional comments regarding your report:

No